2023-08-08 14:22:05 ET
- Inozyme Pharma press release ( NASDAQ: INZY ): Q2 GAAP EPS of -$0.35 beats by $0.08 .
- Cash, cash equivalents, and short-term investments were $140.2 million as of June 30, 2023.
- Based on its current plans, the Company now anticipates its cash, cash equivalents, and short-term investments as of June 30, 2023, together with approximately $64.5 million in proceeds from the July 2023 public offering, will enable the Company to fund its cash flow requirements into Q4 2025.
For further details see:
Inozyme Pharma GAAP EPS of -$0.35 beats by $0.08